Theravance Biopharma Files 8-K: Other Event Reported
Ticker: TBPH · Form: 8-K · Filed: Aug 20, 2025 · CIK: 1583107
| Field | Detail |
|---|---|
| Company | Theravance Biopharma, Inc. (TBPH) |
| Form Type | 8-K |
| Filed Date | Aug 20, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-event
TL;DR
Theravance Biopharma filed an 8-K for an 'Other Event' - no specifics yet.
AI Summary
On August 15, 2025, Theravance Biopharma, Inc. filed an 8-K report detailing an "Other Event." The filing does not contain specific financial figures or significant business updates beyond the reporting of this event.
Why It Matters
This filing indicates a corporate event has occurred, but without further details, its immediate impact on investors or the company's operations is unclear.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting an 'Other Event' without providing specific financial or operational details, thus posing minimal immediate risk.
Key Players & Entities
- Theravance Biopharma, Inc. (company) — Registrant
- August 15, 2025 (date) — Date of earliest event reported
- 001-36033 (other) — Commission File Number
FAQ
What specific event is Theravance Biopharma, Inc. reporting in this 8-K filing?
The filing is categorized under 'Other Events' and does not specify the nature of the event within the provided text.
When was the earliest event reported in this filing?
The earliest event reported was on August 15, 2025.
What is the Commission File Number for Theravance Biopharma, Inc.?
The Commission File Number is 001-36033.
What is the principal executive office address for Theravance Biopharma, Inc.?
The principal executive offices are located at c/o Theravance Biopharma US, LLC, 901 Gateway Boulevard, South San Francisco, CA 94080.
What is the Standard Industrial Classification (SIC) code for Theravance Biopharma, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 587 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2025-08-20 06:05:40
Key Financial Figures
- $0.00001 — e on which registered Ordinary Share $0.00001 Par Value TBPH NASDAQ Global Marke
Filing Documents
- tm2523736d1_8k.htm (8-K) — 24KB
- 0001104659-25-080470.txt ( ) — 185KB
- tbph-20250815.xsd (EX-101.SCH) — 3KB
- tbph-20250815_lab.xml (EX-101.LAB) — 33KB
- tbph-20250815_pre.xml (EX-101.PRE) — 22KB
- tm2523736d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events On August 15, 2025, Theravance Biopharma R&D IP, LLC, Theravance Biopharma US, LLC and Theravance Biopharma Ireland Limited, subsidiaries of the Registrant Theravance Biopharma, Inc. (together, "Theravance"), and Mylan Ireland Limited and Viatris Specialty L.P. (together, "Mylan"), entered into a Settlement Agreement (the "Settlement Agreement") with Cipla Limited and Cipla USA, Inc. ("Cipla") relating to Theravance and Mylan's YUPELRI (revefenacin) inhalation solution. A Theravance entity owns and Mylan is the exclusive sub-licensee of United States Patent Nos. 8,541,451; 9,765,028; 10,550,081; 11,008,289; 11,484,531; 11,691,948; 8,017,783; 9,249,099; 10,100,013; 11,649,209; 11,858,898, 12,048,692 and 12,285,417 (the "Patents-in-Suit"). The Settlement Agreement resolves ongoing patent litigation brought by Theravance and Mylan against Cipla pursuant to the Hatch-Waxman Act based on Cipla's filing of an abbreviated new drug application ("ANDA") seeking approval to market a generic version of YUPELRI (revefenacin) inhalation solution prior to expiration of the Patents-in-Suit. Under the Settlement Agreement, Theravance and Mylan granted Cipla a royalty-free, non-exclusive, non-sublicensable, non-transferable license to manufacture and market Cipla's generic version of YUPELRI (revefenacin) inhalation solution in the United States on or after the Licensed Launch Date of April 23, 2039, subject to certain exceptions as is customary in these type of agreements. As required by law, the settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission. The patent litigation previously disclosed by the Company remains pending against one other ANDA filer: Mankind Pharma Ltd., along with certain affiliates. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THERAVANCE